Work

Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAFV600 mutation–positive metastatic melanoma treated with vemurafenib ± cobimetinib

Year: 2019

Type: article

Source: European Journal of Cancer

DOI: 10.1016/j.ejca.2019.05.002

Authors: Karl Lewis, Axel Hauschild, James Larkin, Antoni Ribas, Keith T. Flaherty, Grant A. McArthur, Brigitte Dréno, Edward McKenna, Qian Zhu, Yong Mun, Paolo A. Ascierto

Institutions: University of Colorado Cancer Center, University Hospital Schleswig-Holstein, Royal Marsden NHS Foundation Trust, University of California, Los Angeles, UCLA Jonsson Comprehensive Cancer Center, Massachusetts General Hospital, The University of Melbourne, Peter MacCallum Cancer Centre, Université de Nantes, Nantes Université, Genentech, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Roche

OpenAlex ID: W2948361993

FWCI: 0.501

Cites: 15

Cited by: 10

Related to: 10